Efficacy of voriconazole versus amphotericin B deoxycholate for empirical antifungal therapy in hematologic malignancy patients with febrile neutropenia: A randomized controlled trial

Faculty of Medicine Siriraj Hospital0 个研究点目标入组 68 人开始时间: 2019年7月17日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Adult age more than 18 years old with hematologic malignancy
•2. Admit at medicine and hemato-oncological ward
•3. Developed febrile neutropenia as definition of IDSA 2010
•4. The febrile neutropenia patient who still have fever after received antimicrobial therapy at least 4 days

•1. Received empirical antifungal therapy more than 24 hours.
•2. Confirm diagnosis of invasive fungal disease
•3. Received empirical antifungal therapy such as posaconazole; which level of posaconazole more than 0.7 microgram/ml, or currently take voriconazole.
•4. History of voriconazole allergy or amphotericin B deoxycholate allergy
•5. Renal insufficiency
•6. Liver impairment
•7. NPO patient
•8. Septic shock or sepsis related hypotension required vasopressor
•9. Suspectation of death in 72 hours
•10. Pregnancy and lactation

发起方